Inhaled Itraconazole Formulation for Idiopathic Pulmonary Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) have limited efficacy and significant side effects, and there is a need for new methods and agents to manage this progressive and fatal lung disease.
Innovation Solution
Administer itraconazole, a known antifungal agent, using a novel dosing regimen and inhalation route, potentially combined with antifibrosis agents like pirfenidone or nintedanib, to treat IPF, utilizing inhalable formulations optimized for direct lung delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifibrosis agents (pirfenidone, nintedanib) are used to treat IPF, then disease progression is slowed, but side effects are significant and dosing regimens are complicated
Solution Approach 1:
The patent changes the physical state parameter of itraconazole from conventional oral solid form to inhaled aerosol form, and modifies the dosing parameter to lower concentrations (e.g., 0.1-10 mg/mL aerosol). This parameter transformation delivers the drug directly to lung tissue while reducing systemic circulation and associated side effects, resolving the contradiction between disease control and harm reduction
Solution Approach 2:
The patent introduces an inhaled aerosol delivery system as an intermediary between the drug (itraconazole) and the target tissue (lung). This intermediary enables localized drug deposition in the lung parenchyma and bronchioles, achieving therapeutic effect while minimizing systemic exposure and side effects
2Reliability
If higher doses of itraconazole are administered to achieve therapeutic effect, then IPF treatment efficacy improves, but side effects and toxicity increase
Solution Approach 1:
The patent applies local quality by concentrating the therapeutic action of itraconazole directly at the site of IPF pathology (lung tissue, bronchioles, and alveoli) through inhaled aerosol delivery. This localized administration achieves high tissue concentration for therapeutic effect while maintaining low systemic concentration, thereby improving efficacy without increasing toxicity
Solution Approach 2:
The patent transforms the administration route parameter from systemic (oral) to local (inhalation), and adjusts the concentration parameter to lower doses (e.g., 1-4 times weekly). This parameter change enables therapeutic efficacy at reduced doses, resolving the contradiction between efficacy and toxicity
3Ease of operation
If oral dosing regimens are used for itraconazole, then administration is convenient, but bioavailability is limited and dosing frequency must be high
Solution Approach 1:
The patent introduces an inhaled aerosol intermediary that bypasses the gastrointestinal absorption barrier. The aerosol particles are directly deposited in the lung where they are absorbed through the alveolar-capillary interface, achieving near 100% local bioavailability without requiring frequent high-dose oral administration
Solution Approach 2:
The patent utilizes pneumatic principles by delivering the drug as an aerosol (气溶胶) that is inhaled through the respiratory tract. This pneumatic delivery system enables direct pulmonary absorption, dramatically improving bioavailability compared to oral administration while maintaining ease of operation through simple inhalation
4Reliability
If approved IPF treatments are used, then some therapeutic benefit is achieved, but the treatments have limited efficacy and require complicated dosing regimens
Solution Approach 1:
The patent employs periodic action by administering inhaled itraconazole aerosol at intervals of 1-4 times weekly rather than continuous daily dosing. This periodic administration maintains therapeutic effect while significantly simplifying the dosing regimen compared to conventional daily oral or IV therapies
Solution Approach 2:
The patent changes the frequency parameter from daily to weekly (1-4 times), and transforms the administration route to inhaled aerosol. This parameter transformation simplifies the dosing regimen while maintaining or improving therapeutic benefit, resolving the contradiction between efficacy and regimen complexity
Data Source
AI summary
Provided is a pharmaceutical composition comprising an effective amount of itraconazole, and a pharmaceutically acceptable excipient. The use of the pharmaceutical composition for treatment of idiopathic pulmonary fibrosis is also provided.